Software Update Available for all t:slim® Insulin Pumps Purchased
Before April 2015
SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and
manufacturer of the only touchscreen insulin pumps available in the
United States, today announced the release of a software update for
t:slim® Insulin Pumps purchased before April 2015. The software update
will be available via personal computer using the Tandem Device Updater,
a Mac® and PC-compatible tool for the remote deployment of Tandem
insulin pump software. This represents the first time an insulin pump
manufacturer has provided a software update for customers using their
"The innovative, first-of-its-kind Tandem Device Updater represents an
important advancement in the way functionality is delivered to insulin
pump users, making it possible to provide new pump features to our
customers independent of the typical pump insurance replacement cycle,"
said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. "We
are working on exciting new software updates to offer our customers as
they are approved by the FDA, such as integration with Dexcom's G5
Mobile CGM system and automated insulin delivery algorithms, and today's
launch is the first step in this direction."
The software update launched today provides the latest t:slim Insulin
Pump software to in-warranty t:slim Pumps purchased before April 2015.
The features included in this software release began shipping on new
t:slim Pumps in April 2015, and include a variety of product
enhancements for convenience and flexibility.
In-warranty customers who purchased their t:slim Pump before April
2015 will receive an email in the next three weeks with their unique
Update ID Number and instructions on how to update their pump.
Consistent with past product development efforts, the design of the
Tandem Device Updater was driven significantly by direct input from pump
users. Following clearance by the U.S. Food and Drug Administration,
Tandem conducted additional customer testing to further refine the user
experience. Approximately two thirds of the 300 customers who
participated in the beta release completed a survey after their
download. Survey results reported that the product was easy to use, with
more than 90% indicating they would be likely to download future
To learn more about the Tandem Device Updater, visit www.tandemdiabetes.com/updater.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company with an innovative, user-centric and
integrated approach to the design, development and commercialization of
products for people with diabetes who use insulin. The Company
manufactures and sells the t:slim X2™ Insulin Pump, the slimmest and
smallest durable insulin pump currently on the market, the t:flex®
Insulin Pump, the first pump designed for people with greater insulin
requirements, and the t:slim G4™ Insulin Pump, the first continuous
glucose monitoring-enabled pump with touchscreen simplicity. Tandem is
based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2,
#tslimG4, #tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care
on Facebook at www.facebook.com/TandemDiabetes.
Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
t:slim, t:flex, and Tandem Diabetes Care are registered trademarks, and
t:slim X2 and t:slim G4 are trademarks of Tandem Diabetes Care, Inc. All
other trademarks are the property of their respective owners.
Forward Looking Statement
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
include statements regarding the Company's ability to offer future
software improvements and enhancements to Tandem pumps using the Tandem
Device Updater and the Company's ongoing development activities for
integration of Dexcom's G5 sensor and automated insulin delivery
algorithms. The Company's actual results may differ materially from
those indicated in these forward-looking statements due to numerous
risks and uncertainties. For instance, successful commercialization of
the Company's products, including the Tandem Device Updater, may be
negatively impacted by lack of market acceptance by physicians, payors
and people with diabetes; the potential that newer products that compete
with the Company's products, or other technological breakthroughs for
the monitoring, treatment or prevention of diabetes, may render the
Company's products, including the Tandem Device Updater, obsolete or
less desirable; the potential that the Tandem Device Updater may fail to
perform according to its specifications or may not provide people with
diabetes with anticipated benefits; and the potential that the Company
may not be able to successfully complete the development of some or all
of the future software improvements and enhancements to Tandem pumps, or
that those software improvements and enhancements may not be approved by
the FDA in a timely manner or at all. Other risks and uncertainties are
identified in the Company's most recent Annual Report on Form 10-K and
Quarterly Report on Form 10-Q, and other documents that the Company
files with the Securities and Exchange Commission. Investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release. Tandem
undertakes no obligation to update or review any forward-looking
statement in this press release because of new information, future
events or other factors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170302005173/en/
Tandem Diabetes Care, Inc.
Susan Morrison, 858-366-6900 x7005
Source: Tandem Diabetes Care, Inc.
News Provided by Acquire Media